Transformers 4 Will Be a Chinese Co-Production

Here's a very simple lesson in Hollywood economics. When someone makes a movie that grosses comfortably over a hundred million dollars in some other, non-US territory, the studio responsible will do whatever it takes to maximize the presence of the sequel in that same territory. And so it comes as no surprise to learn that with Hollywood in general casting lusting eyes at the massive Chinese market and with Michael Bay's Transformers 3 grossing $165 million in the Chinese mainland, the upcoming Mark Wahlberg starring Transformers 4 will be an official Chinese co-production.

The trade off is pretty much a no brainer from a production standpoint. In exchange for including some Chinese cast - cast always being a secondary concern in these films anyway - and shooting in some Chinese locations, the producers get direct investment from China Movie Channel and Jiaflix Enterprises while also guaranteeing that the film can be released wide across the country without the hassle of having to be selected as one of the limited number of foreign productions allowed in via the restrictive import laws.

Sure, the China Movie Channel is a government organization run directly by SARFT - responsible for film censorship, among other things - but, hey. Nobody seems to watch these things for story, either, so it's not like it really matters what requirements may be placed there, right?

Source: http://www.rottentomatoes.com/m/1927162/news/1927162/

slither naacp glen campbell jerusalem artichoke bud shootout aretha franklin stevie wonder

Kate Hudson: Matthew Proved Himself When I Got Pregnant

"It was all very old-fashioned and proper, and we went on lovely dates," Hudson, 33, tells ELLE UK in their May issue.

Source: http://feeds.celebritybabies.com/~r/celebrity-babies/~3/MgQRD_oYaxs/

pulitzer prize winners nfl 2012 schedule gmail down tim lincecum ryan oneal file taxes online tupac shakur

Caroline Kennedy to be named ambassador to Japan (Washington Post)

Share With Friends: | | Politics - Top Stories News, RSS Feeds and Widgets via Feedzilla.

Source: http://news.feedzilla.com/en_us/stories/politics/top-stories/295949350?client_source=feed&format=rss

indianapolis colts joseph kony joseph kony ipad 3 release date apple store down apple live blog ohio primary

'G.I. Joe' earns $40.5M at weekend box office

LOS ANGELES (AP) ? "G.I. Joe: Retaliation" conquered the weekend box office.

The shoot-'em-up sequel starring Dwayne "The Rock" Johnson, Bruce Willis and Channing Tatum as the military action figures brought to life earned $40.5 million over the weekend.

The top 20 movies at U.S. and Canadian theaters Friday through Sunday, followed by distribution studio, gross, number of theater locations, average receipts per location, total gross and number of weeks in release, as compiled Monday by Hollywood.com are:

1. "G.I. Joe: Retaliation," Paramount, $40,501,814, 3,719 locations, $10,891 average, $51,008,689, one week.

2. "The Croods," Fox/DreamWorks Animation, $26,705,868, 4,065 locations, $6,570 average, $88,887,945, two weeks.

3. "Tyler Perry's Temptation," Lionsgate, $21,641,679, 2,047 locations, $10,572 average, $21,641,679, one week.

4. "Olympus Has Fallen," FilmDistrict, $14,147,416, 3,106 locations, $4,555 average, $54,890,085, two weeks.

5. "Oz the Great and Powerful," Disney, $11,702,316, 3,324 locations, $3,521 average, $198,374,716, four weeks.

6. "The Host," Open Road Films, $10,600,112, 3,202 locations, $3,310 average, $10,600,112, one week.

7. "The Call," Sony, $4,925,675, 2,439 locations, $2,020 average, $39,605,891, three weeks.

8. "Admission," Focus Features, $3,235,263, 2,161 locations, $1,497 average, $11,744,141, two weeks.

9. "Spring Breakers," A24, $2,774,145, 1,379 locations, $2,012 average, $10,074,434, three weeks.

10. "The Incredible Burt Wonderstone," Warner Bros., $1,343,025, 1,575 locations, $853 average, $20,629,646, three weeks.

11. "Identity Thief," Universal, $1,098,215, 1,082 locations, $1,015 average, $129,916,105, eight weeks.

12. "Jack the Giant Slayer," Warner Bros., $1,019,062, 1,080 locations, $944 average, $61,399,384, five weeks.

13. "Silver Linings Playbook," Weinstein Co., $900,927, 752 locations, $1,198 average, $128,712,563, 20 weeks.

14. "Snitch," Lionsgate, $444,457, 746 locations, $596 average, $41,353,859, six weeks.

15. "Life of Pi," Fox, $427,260, 340 locations, $1,257 average, $123,321,125, 19 weeks.

16. "Safe Haven," Relativity Media, $387,754, 550 locations, $705 average, $69,811,436, seven weeks.

17. "Quartet," Weinstein Co., $382,271, 302 locations, $1,266 average, $16,599,664, 12 weeks.

18. "21 and Over," Relativity Media, $302,277, 344 locations, $879 average, $24,952,089, five weeks.

19. "The Place Beyond the Pines," Focus, $279,457, 4 locations, $69,864 average, $279,457, one week.

20. "Escape From Planet Earth," Weinstein Co., $235,117, 977 locations, $241 average, $53,927,096, seven weeks.

___

Universal and Focus are owned by NBC Universal, a unit of Comcast Corp.; Sony, Columbia, Sony Screen Gems and Sony Pictures Classics are units of Sony Corp.; Paramount is owned by Viacom Inc.; Disney, Pixar and Marvel are owned by The Walt Disney Co.; Miramax is owned by Filmyard Holdings LLC; 20th Century Fox and Fox Searchlight are owned by News Corp.; Warner Bros. and New Line are units of Time Warner Inc.; MGM is owned by a group of former creditors including Highland Capital, Anchorage Advisors and Carl Icahn; Lionsgate is owned by Lions Gate Entertainment Corp.; IFC is owned by AMC Networks Inc.; Rogue is owned by Relativity Media LLC.

Source: http://news.yahoo.com/g-joe-earns-40-5m-weekend-box-office-223027030.html

Calendar 2013 john boehner HGTV Dream Home 2013 eric cantor eric cantor HGTV Sugar Bowl 2013

The Walking Dead Season 4: Who Will Return?

Source: http://www.thehollywoodgossip.com/2013/04/the-walking-dead-season-4-who-will-return/

progeria what will my baby look like gary carter died cmas cmas tcu dr. oz

Understanding statin discontinuation

Public release date: 1-Apr-2013
[ | E-mail | Share ]

Contact: Jessica Maki
jmaki3@partners.org
617-534-1603
Brigham and Women's Hospital

Brigham and Women's Hospital study examines the role adverse reactions play in statin discontinuation

Boston, MA-- Despite their well-documented benefits, statins, drugs used to lower cholesterol, are commonly discontinued in routine care. Statin discontinuation has been linked to increased risk for cardiovascular events and death in patients with coronary artery disease; nevertheless, the reasons for discontinuation are only starting to be explored. In a new study from Brigham and Women's Hospital (BWH), researchers examined the role adverse reactions play in statin discontinuation and found that more than 90 percent of the patients who stopped taking a statin due to an adverse reaction, were able to tolerate it when they tried again. This study is published in the April 2, 2013 issue of the Annals of Internal Medicine.

"We were particularly interested in the role adverse reactions play in statin discontinuation," explained Alexander Turchin, MD, MS, a physician and researcher in the Division of Endocrinology at BWH and the senior author of the paper. "In my own clinical experience, I have found that many patients report adverse reactions to statins, such as muscle pain, and then stop taking them. At the same time, we often find that patients who had previously stopped taking a statin because of these adverse reactions, are ultimately able to tolerate them again the second time around."

The researchers examined clinical data from over 107,835 patients between 2000-2008, who were prescribed a statin. They used validated computational text analysis software in an electronic medical record (EMR) system to analyze statin discontinuation and identified patients who had statin-related events (possible side effects to statins), whether people stopped taking their statins after these events, whether they later restarted a statin, and what happened if they did.

The researchers found that approximately one fifth of people had a symptom or other event that may have been related to the drug, and more than half of these people stopped taking their statin, at least temporarily. More than half of the people who stopped because of an event started taking a statin again (although not necessarily the same one), and more than 90 percent of them continued taking the statin after restarting.

"We interpret these results as a glass half-full, meaning that there are potentially millions of patients who could take statins again, and ultimately reduce their risk of heart disease," explained Turchin. This study provides important take home messages for both patients and physicians. For patients, it's important to understand that just because you may have had an adverse reaction to a statin, that does not necessarily mean you should stop taking them altogether. For physicians, it's important to suggest to the patient that many times these drugs can be tolerated, and it may be time to try another statin or perhaps a lower dose

Researchers suggest that it is also important to conduct a clinical trial to determine whether rechallenging patients after statin-related events improves outcomes.

###

This research was supported by the National Library of Medicine, Diabetes Action Research and Education Foundation, and Chinese National Key Program of Clinical Science.

Brigham and Women's Hospital (BWH) is a 793-bed nonprofit teaching affiliate of Harvard Medical School and a founding member of Partners HealthCare. BWH has more than 3.5 million annual patient visits, is the largest birthing center in New England and employs more than 15,000 people. The Brigham's medical preeminence dates back to 1832, and today that rich history in clinical care is coupled with its national leadership in patient care, quality improvement and patient safety initiatives, and its dedication to research, innovation, community engagement and educating and training the next generation of health care professionals. Through investigation and discovery conducted at its Biomedical Research Institute (BRI), BWH is an international leader in basic, clinical and translational research on human diseases, involving nearly 1,000 physician-investigators and renowned biomedical scientists and faculty supported by nearly $625 million in funding. BWH continually pushes the boundaries of medicine, including building on its legacy in organ transplantation by performing the first face transplants in the U.S. in 2011. BWH is also home to major landmark epidemiologic population studies, including the Nurses' and Physicians' Health Studies, OurGenes and the Women's Health Initiative. For more information and resources, please visit BWH's online newsroom.

---

[ | E-mail | Share ]

?

AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.

Public release date: 1-Apr-2013
[ | E-mail | Share ]

Contact: Jessica Maki
jmaki3@partners.org
617-534-1603
Brigham and Women's Hospital

Brigham and Women's Hospital study examines the role adverse reactions play in statin discontinuation

Boston, MA-- Despite their well-documented benefits, statins, drugs used to lower cholesterol, are commonly discontinued in routine care. Statin discontinuation has been linked to increased risk for cardiovascular events and death in patients with coronary artery disease; nevertheless, the reasons for discontinuation are only starting to be explored. In a new study from Brigham and Women's Hospital (BWH), researchers examined the role adverse reactions play in statin discontinuation and found that more than 90 percent of the patients who stopped taking a statin due to an adverse reaction, were able to tolerate it when they tried again. This study is published in the April 2, 2013 issue of the Annals of Internal Medicine.

"We were particularly interested in the role adverse reactions play in statin discontinuation," explained Alexander Turchin, MD, MS, a physician and researcher in the Division of Endocrinology at BWH and the senior author of the paper. "In my own clinical experience, I have found that many patients report adverse reactions to statins, such as muscle pain, and then stop taking them. At the same time, we often find that patients who had previously stopped taking a statin because of these adverse reactions, are ultimately able to tolerate them again the second time around."

The researchers examined clinical data from over 107,835 patients between 2000-2008, who were prescribed a statin. They used validated computational text analysis software in an electronic medical record (EMR) system to analyze statin discontinuation and identified patients who had statin-related events (possible side effects to statins), whether people stopped taking their statins after these events, whether they later restarted a statin, and what happened if they did.

The researchers found that approximately one fifth of people had a symptom or other event that may have been related to the drug, and more than half of these people stopped taking their statin, at least temporarily. More than half of the people who stopped because of an event started taking a statin again (although not necessarily the same one), and more than 90 percent of them continued taking the statin after restarting.

"We interpret these results as a glass half-full, meaning that there are potentially millions of patients who could take statins again, and ultimately reduce their risk of heart disease," explained Turchin. This study provides important take home messages for both patients and physicians. For patients, it's important to understand that just because you may have had an adverse reaction to a statin, that does not necessarily mean you should stop taking them altogether. For physicians, it's important to suggest to the patient that many times these drugs can be tolerated, and it may be time to try another statin or perhaps a lower dose

Researchers suggest that it is also important to conduct a clinical trial to determine whether rechallenging patients after statin-related events improves outcomes.

###

This research was supported by the National Library of Medicine, Diabetes Action Research and Education Foundation, and Chinese National Key Program of Clinical Science.

Brigham and Women's Hospital (BWH) is a 793-bed nonprofit teaching affiliate of Harvard Medical School and a founding member of Partners HealthCare. BWH has more than 3.5 million annual patient visits, is the largest birthing center in New England and employs more than 15,000 people. The Brigham's medical preeminence dates back to 1832, and today that rich history in clinical care is coupled with its national leadership in patient care, quality improvement and patient safety initiatives, and its dedication to research, innovation, community engagement and educating and training the next generation of health care professionals. Through investigation and discovery conducted at its Biomedical Research Institute (BRI), BWH is an international leader in basic, clinical and translational research on human diseases, involving nearly 1,000 physician-investigators and renowned biomedical scientists and faculty supported by nearly $625 million in funding. BWH continually pushes the boundaries of medicine, including building on its legacy in organ transplantation by performing the first face transplants in the U.S. in 2011. BWH is also home to major landmark epidemiologic population studies, including the Nurses' and Physicians' Health Studies, OurGenes and the Women's Health Initiative. For more information and resources, please visit BWH's online newsroom.

---

[ | E-mail | Share ]

?

AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.

Source: http://www.eurekalert.org/pub_releases/2013-04/bawh-usd032713.php

annapolis wwe royal rumble trisomy leon panetta luck sag awards 2012 nominees pro bowl 2012 roster

Study reveals how diabetes drug delays ageing in worms - Health.am

? Drug News ? Mar 31, 2013

A widely prescribed type 2 diabetes drug slows down the ageing process by mimicking the effects of dieting, according to a study published today using worms to investigate how the drug works.

Following a calorie-restricted diet has been shown to improve health in later life and extend lifespan in a number of animals, ranging from the simple worm to rhesus monkeys. The type 2 diabetes drug metformin has been found to have similar effects in animals but until now it was not clear exactly how the drug delays the ageing process.

Researchers supported by the Wellcome Trust and Medical Research Council looked at the effects of metformin on C. elegans worms that were grown in the presence of E. coli bacteria, a relationship similar to that which humans have with the ?healthy? bacteria in our gut. They found that the worms treated with metformin lived longer only when the E. coli strain they were cultured with was sensitive to the drug.

Dr Filipe Cabreiro from the Institute of Healthy Ageing at UCL, who led the research, explains: ?Overall, treatment with metformin adds up to 6 days of life for the worm which is equivalent to around a third of its normal lifespan. It seems to work by altering metabolism in the bacteria that live in the worm, which in turn limits the nutrients that are available to the worm host and has a similar effect to restricting the diet.?

Bacteria living in the gut have an important role in helping the host organism to digest and extract nutrition from food. Defects in gut bacteria have been linked to metabolic diseases such as obesity, diabetes, inflammatory bowel disease and cancer. It has also been suggested that gut bacteria may have an impact on the ageing process, but this is the first study to suggest a mechanism for how this works.

The team used strains of E. coli with defects in genes that are linked to metabolism and tweaked the levels of nutrients available to tease out which metabolic pathways might be affected by the drug. They found that treatment with metformin disrupted the bacteria?s ability to metabolise folate, a type of B-vitamin, and methionine, one of the building blocks of proteins. This limits the nutrients that are available to the worm and mimics the effects of dietary restriction to enable the worms to live longer.

However, when they added an excess of sugar to the diet, the team found that the life-extending effects of metformin were cancelled out. As the drug is used as a treatment for diabetes caused by elevated glucose levels in the blood, this finding is particular relevant for understanding how the drug works in people.

Professor David Gems, who directed the study, said: ?We don?t know from this study whether metformin has any effect on human ageing. The more interesting finding is the suggestion that drugs that alter bacteria in the gut could give us a new way of treating or preventing metabolic diseases like obesity and diabetes.?

Metformin is currently one of the most widely prescribed drugs and the findings should help to inform how it is used in patients.

The study was published today, Thursday 28 March, in the journal Cell.

###

Jen Middleton
j.middleton@wellcome.ac.uk
44-207-611-7262
Wellcome Trust

Provided by ArmMed Media

?Comments

[ + Post Your Own ]?

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]

Source: http://www.health.am/ab/more/diabetes-drug-delays-ageing-in-worms/

vince young evan longoria john edwards conocophillips capitals ryan braun bryce harper